BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 30, 2005
View Archived Issues
Cypress' Stock Plunges After Phase III Miss In Fibromyalgia
Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today)
Read More
Sirna's RNAi Work Lands $250M Deal With Allergan
Read More
New Research: Target Host Cells To Help Fight Viruses
Read More
Avalon Sets IPO Price: $28.9M Pipeline Boost
Read More
Genomic Health's IPO Adds $60M For Breast Cancer Test
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
U.S. Patent Disclosures
Read More